Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$0.91 - $4.16 $19,622 - $89,702
-21,563 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$3.78 - $5.18 $36,926 - $50,603
9,769 Added 82.83%
21,563 $89,000
Q2 2021

Aug 16, 2021

SELL
$4.1 - $5.33 $177,144 - $230,287
-43,206 Reduced 78.56%
11,794 $51,000
Q1 2021

May 17, 2021

BUY
$4.93 - $7.15 $99,586 - $144,430
20,200 Added 58.05%
55,000 $277,000
Q4 2020

Feb 16, 2021

SELL
$4.55 - $7.29 $28,715 - $46,007
-6,311 Reduced 15.35%
34,800 $220,000
Q3 2020

Nov 16, 2020

BUY
$4.22 - $6.04 $81,070 - $116,034
19,211 Added 87.72%
41,111 $177,000
Q2 2020

Aug 14, 2020

SELL
$3.76 - $8.01 $7,704 - $16,412
-2,049 Reduced 8.56%
21,900 $129,000
Q1 2020

May 15, 2020

BUY
$3.5 - $8.51 $42,871 - $104,238
12,249 Added 104.69%
23,949 $105,000
Q4 2019

Feb 14, 2020

SELL
$4.52 - $7.91 $73,224 - $128,142
-16,200 Reduced 58.06%
11,700 $80,000
Q2 2019

Aug 14, 2019

BUY
$7.08 - $10.6 $197,532 - $295,740
27,900 New
27,900 $206,000

Others Institutions Holding CBIO

# of Institutions
1
Shares Held
215
Call Options Held
0
Put Options Held
0

About CATALYST BIOSCIENCES, INC.


  • Ticker CBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,477,100
  • Description
  • Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...
More about CBIO
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.